Researchers at Macau University of Science and Technology discover ZYZ-384, a potent SMYD3 inhibitor that suppresses H3K4 trimethylation to lower senescence markers in human endothelial cells and mouse aging models, restoring cell proliferation and tissue function.
Key points
- ZYZ-384 selectively inhibits SMYD3 histone methyltransferase, reducing H3K4me3 in endothelial cells.
- Administered in vitro (HMEC-1, SVEC4-10) and in vivo (D-galactose and natural aging mouse models) to evaluate anti-senescence.
- Results show reduced p16/p21, lowered SASP cytokines, improved cell proliferation and motor performance.
Why it matters: This targeted SMYD3 inhibitor offers a novel epigenetic approach to slow aging processes and improve healthspan.
Q&A
- What is SMYD3?
- How does ZYZ-384 inhibit aging?
- Why use the D-galactose model?
- What is SASP and its relevance?